PATH | VRL
Menu

Efficacy, Safety, and Immunogenicity of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Women Older Than 25 Years: 4-Year Interim Follow-Up of the Phase 3, Double-Blind, Randomised Controlled VIVIANE Study

This article, published in The Lancet, discusses the results of an efficacy, safety, and immunogenicity study of the human papillomavirus (HPV) 16/18 vaccine in adult women. The results showed that in women older than 25 years, the HPV 16/18 vaccine is efficacious against infections and cervical abnormalities associated with the vaccine types, as well as infections with the non-vaccine HPV types 31 and 45. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Skinner SR, Szarewski A, Romanowski B, et al.

Published: 2014

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, Safety, and Immunogenicity of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Women Older Than 25 Years: 4-Year Interim Follow-Up of the Phase 3, Double-Blind, Randomised Controlled VIVIANE Study. The Lancet. 2014;Early Online Publication.

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV)

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Global